The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The use of PET and ctDNA for risk stratification & to guide treatment decisions in Hodgkin lymphoma
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, provides insight into emerging techniques to individualize and guide treatment for patients with Hodgkin lymphoma (HL), highlighting the advantages and disadvantages of PET-guided therapy and discussing the use of ctDNA measurable residual disease (MRD) detection. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
